{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T22:43:32Z","timestamp":1789425812014,"version":"build-2803163510"},"reference-count":248,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Immunohistochemistry (IHC) is a keystone in gastric cancer (GC) management, allowing treatment customization, including for advanced or metastatic diseases. This review aims to evaluate the critical role of IHC markers, analyzing their efficiency in molecular subclassification and prediction of response to gastric cancer-targeted therapies, while also describing state-of-the-art IHC techniques and perspectives. Results: The major challenges for the GC management were structured in two main sections, as follows: (i) the current paradigm of gastric neoplasia diagnosis, which includes subsections related to the methodological and morphological foundations, the epidemiological dynamics, and risk factors, as well as differential diagnosis of poorly differentiated tumors; and (ii) the progress in 3,3\u2032-diaminobenzidine (DAB) application and advanced reagents in gastric cancer immunohistochemistry. Discussion: Considering the role of IHC and DAB, the following topics were successively addressed in seven sections: GC key biomarkers, such as human epidermal growth factor receptor 2 (HER2), programmed death-ligand 1 (PD-L1), and DNA replication mismatch repair (MMR) system, allow direct correlation between tissue morphology and protein expression; intestinal and gastrointestinal differentiation markers; emerging and aggressive histological subtypes; epithelial\u2013mesenchymal transition, E-cadherin, and the process of tumor budding; implementation of innovative procedures in gastric cancer immunohistochemistry; and automation, quality control, and sustainability in the pathology laboratory. Perspectives: The main directions were focused on the integration of artificial intelligence (AI) algorithms for digital quantification of the IHC signal and also on the expansion of panels to new targets, such as Claudin 18.2 (CLDN 18.2), which redefines treatment approaches in advanced stages. Conclusions: Although faced with technical and biological limitations, immunohistochemistry remains indispensable in modern gastric oncology. The evolution towards digital pathology and the refinement of scoring criteria will transform IHC from a complementary test into a visual tool that is essential for personalizing oncological treatment.<\/jats:p>","DOI":"10.3390\/medicina62040683","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T04:10:27Z","timestamp":1775448627000},"page":"683","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comprehensive Overview of Gastric Cancer Immunohistochemistry: Key Biomarkers, Advanced Detection Methods, and Perspectives"],"prefix":"10.3390","volume":"62","author":[{"given":"Bogdan","family":"Oprea","sequence":"first","affiliation":[{"name":"Department 1\u2013Histology, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, Petru Rares, 2, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Agrawal, R., Jurel, P., Garg, A., Prajapati, B.G., and Ashique, S. (2025). Advances in Gastric Cancer Management: Signaling Pathways, Emerging Diagnostic and Therapeutic Strategies. Cancer Biother. Radiopharm., 10849785251408598.","DOI":"10.1177\/10849785251408598"},{"key":"ref_2","first-page":"100845","article-title":"Gastric cancer\u2014Epidemiology, modifiable and non-modifiable risk factors, challenges and opportunities: An updated review","volume":"41","author":"Mamun","year":"2024","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3390\/hygiene3030019","article-title":"Gastric Cancer Epidemiology: Current Trend and Future Direction","volume":"3","author":"Iwu","year":"2023","journal-title":"Hygiene"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41392-022-01190-w","article-title":"Signaling pathways and therapeutic interventions in gastric cancer","volume":"7","author":"Lei","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S350","DOI":"10.21037\/jgo-2019-gi-05","article-title":"Gastric cancer: Lessons learned from high-incidence geographic regions","volume":"12","author":"Abengozar","year":"2021","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4132\/jptm.2022.12.23","article-title":"The Gastrointestinal Pathology Study Group of the Korean Society of Pathologists. A standardized pathology report for gastric cancer: 2nd edition","volume":"57","author":"Park","year":"2023","journal-title":"J. Pathol. Transl. Med."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Yong, W. (2019). An Introduction to the Performance of Immunohistochemistry. Biobanking, Humana Press. Methods in Molecular Biology.","DOI":"10.1007\/978-1-4939-8935-5"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/PAP.0000000000000256","article-title":"An Algorithmic Immunohistochemical, Approach to Define Tumor Type and Assign Site of Origin","volume":"27","author":"Bellizzi","year":"2020","journal-title":"Adv. Anat. Pathol."},{"key":"ref_9","first-page":"868645","article-title":"Immunohistochemical biomarkers in gastric cancer research and management","volume":"2012","author":"Lastraioli","year":"2012","journal-title":"Int. J. Surg. Oncol."},{"key":"ref_10","first-page":"169","article-title":"Immunohistochemistry in diagnostic surgical pathology: Contributions of protein life-cycle, use of evidence-based methods and data normalization on interpretation of immunohistochemical stains","volume":"3","author":"Idikio","year":"2009","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1053\/j.semdp.2021.10.003","article-title":"Immunohistochemistry as predictive and prognostic markers for gastrointestinal malignancies","volume":"39","author":"Rosenbaum","year":"2022","journal-title":"Semin. Diagn. Pathol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"155145","DOI":"10.1016\/j.prp.2024.155145","article-title":"Claudin-18.2 testing and its impact in the therapeutic management of patients with gastric and gastroesophageal adenocarcinomas: A literature review with expert opinion","volume":"254","author":"Angerilli","year":"2024","journal-title":"Pathol. Res. Pract."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Prodan-B\u0103rbulescu, C., Faur, F.I., Varga, N.I., Hajjar, R., Pa\u0219ca, P., Ghenciu, L.A., Feier, C.I.V., Dema, A., F\u0103rcu\u021b, N., and Bolintineanu, S. (2025). A Histopathological and Surgical Analysis of Gastric Cancer: A Two-Year Experience in a Single Center. Cancers, 17.","DOI":"10.3390\/cancers17132219"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1007\/s13402-024-00951-9","article-title":"Research advances in the molecular classification of gastric cancer","volume":"47","author":"Shi","year":"2024","journal-title":"Cell. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s40944-024-00875-0","article-title":"Immunohistochemistry as an Indispensable Tool in Oncology","volume":"22","author":"Kabir","year":"2024","journal-title":"Indian. J. Gynecol. Oncolog."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Scheck, M.K., Hofheinz, R.D., and Lorenzen, S. (2024). HER2-Positive Gastric Cancer and Antibody Treatment: State of the Art and Future Developments. Cancers, 16.","DOI":"10.3390\/cancers16071336"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13045-022-01325-0","article-title":"Immune checkpoint modulators in cancer immunotherapy: Recent advances and emerging concepts","volume":"15","author":"Wang","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e70176","DOI":"10.1002\/mco2.70176","article-title":"Application of Immune Checkpoint Inhibitors in Cancer","volume":"6","author":"Chen","year":"2025","journal-title":"MedComm"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"100242","DOI":"10.1016\/j.esmogo.2025.100242","article-title":"Real-world treatment patterns and outcomes in advanced\/metastatic gastric cancer or gastroesophageal junction adenocarcinoma treated with first-line anti-HER2 therapy in England","volume":"10","author":"Starling","year":"2025","journal-title":"ESMO Gastrointest. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"16231","DOI":"10.1007\/s00432-023-05180-5","article-title":"Standardized and quality-assured predictive PD-L1 testing in the upper gastrointestinal tract","volume":"149","author":"Baretton","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Lordick, F., Rha, S.Y., Muro, K., Yong, W.P., and Obermannov\u00e1, R.L. (2024). Systemic Therapy of Gastric Cancer-State of the Art and Future Perspectives. Cancers, 16.","DOI":"10.3390\/cancers16193337"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"411","DOI":"10.4132\/jptm.2016.08.08","article-title":"Immunohistochemistry for Pathologists: Protocols, Pitfalls, and Tips","volume":"50","author":"Kim","year":"2016","journal-title":"J. Pathol. Transl. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1007\/s12094-025-03865-6","article-title":"Biomarkers in gastroesophageal cancer 2025: An updated consensus statement by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP)","volume":"27","author":"Cuatrecasas","year":"2025","journal-title":"Clin. Transl. Oncol."},{"key":"ref_24","first-page":"8","article-title":"Predictive biomarkers for immunotherapy in gastric cancer","volume":"11","author":"Li","year":"2025","journal-title":"J. Cancer Metastasis Treat."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"156068","DOI":"10.1016\/j.prp.2025.156068","article-title":"Immunohistochemical biomarker scoring in gastroesophageal cancers: Can computers help us?","volume":"272","author":"Caputo","year":"2025","journal-title":"Pathol. Res. Pract."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"9421571","DOI":"10.1155\/2016\/9421571","article-title":"MUC1 Immunohistochemical Expression as a Prognostic Factor in Gastric Cancer: Meta-Analysis","volume":"2016","author":"Wang","year":"2016","journal-title":"Dis. Markers"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Mihaila, R.I., Gheorghe, A.S., Zob, D.L., and Stanculeanu, D.L. (2024). The Importance of Predictive Biomarkers and Their Correlation with the Response to Immunotherapy in Solid Tumors-Impact on Clinical Practice. Biomedicines, 12.","DOI":"10.3390\/biomedicines12092146"},{"key":"ref_28","first-page":"10","article-title":"Biomarker prediction of immunotherapy response in breast cancer: From single markers to multi-omics integration","volume":"12","author":"Lu","year":"2026","journal-title":"npj Breast Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e000791","DOI":"10.1136\/esmoopen-2020-000791","article-title":"Current status and future potential of predictive biomarkers for immune checkpoint inhibitors in gastric cancer","volume":"5","author":"Kang","year":"2020","journal-title":"ESMO Open"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"11795549241298541","DOI":"10.1177\/11795549241298541","article-title":"Cancer Biomarkers and Precision Oncology: A Review of Recent Trends and Innovations","volume":"18","author":"AlDoughaim","year":"2024","journal-title":"Clin. Med. Insights Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Das, S., Dey, M.K., Devireddy, R., and Gartia, M.R. (2024). Biomarkers in Cancer Detection, Diagnosis, and Prognosis. Sensors, 24.","DOI":"10.3390\/s24010037"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1186\/s40001-025-03003-6","article-title":"Emerging biomarkers for early cancer detection and diagnosis: Challenges, innovations, and clinical perspectives","volume":"30","author":"Zafar","year":"2025","journal-title":"Eur. J. Med. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.cell.2024.02.041","article-title":"Cancer biomarkers: Emerging trends and clinical implications for personalized treatment","volume":"187","author":"Passaro","year":"2024","journal-title":"Cell"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e70863","DOI":"10.1002\/cam4.70863","article-title":"Immunohistochemical-Based Molecular Typing of ACRG Combined with Immune-Associated PD-L1 Expression Can Predict the Prognosis of Gastric Cancer","volume":"14","author":"Li","year":"2025","journal-title":"Cancer Med."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Nshizirungu, J.P., Bennis, S., Mellouki, I., Sekal, M., Benajah, D.A., Lahmidani, N., El Bouhaddouti, H., Ibn Majdoub, K., Ibrahimi, S.A., and Celeiro, S.P. (2021). Reproduction of the Cancer Genome Atlas (TCGA) and Asian Cancer Research Group (ACRG) Gastric Cancer Molecular Classifications and Their Association with Clinicopathological Characteristics and Overall Survival in Moroccan Patients. Dis. Markers, 9980410.","DOI":"10.1155\/2021\/9980410"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Yoon, J.-Y., Sy, K., Brezden-Masley, C., and Streutker, C.J. (2019). Histo- and immunohistochemistry-based estimation of the TCGA and ACRG molecular subtypes for gastric carcinoma and their prognostic significance: A single-institution study. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0224812"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.15190\/d.2018.6","article-title":"HER2 Oncogene Amplification and Immunohistochemical Profiling in Gastric Adenocarcinoma","volume":"6","author":"Raj","year":"2018","journal-title":"Discoveries"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"103038","DOI":"10.1016\/j.ctrv.2025.103038","article-title":"Precision oncology in gastric cancer: Shaping the future of personalized treatment","volume":"141","author":"Migliore","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"ref_39","first-page":"640","article-title":"Tissue Biomarkers in Gastric Cancer Treatment: Present and Future","volume":"4","author":"Agnetti","year":"2024","journal-title":"Int. J. Transl. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"115191","DOI":"10.1016\/j.intimp.2025.115191","article-title":"Decoding inflammatory mediators in the Correa\u2019s cascade: From chronic gastritis to carcinogennesis and targeted therapies","volume":"162","author":"Zhou","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"63","DOI":"10.62347\/JVIX8887","article-title":"Unique immunohistochemical profiles of MUC5AC, MUC6, P53, and Ki67 in gastric atypical hyperplasia and dysplasia","volume":"17","author":"Miao","year":"2024","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"273","DOI":"10.5230\/jgc.2022.22.e35","article-title":"Molecular Pathology of Gastric Cancer","volume":"22","author":"Kim","year":"2022","journal-title":"J. Gastric Cancer."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Lv, M., Chen, F., Li, Q., Xue, M., and Wang, J. (2025). Comparative diagnostic accuracy of different artificial intelligence models for early gastric cancer: A systematic review and meta-analysis. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1670843"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4884","DOI":"10.1038\/s41467-021-25221-2","article-title":"Deep learning-based transformation of H&E stained tissues into special stains","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1038\/s42256-024-00889-5","article-title":"Accelerating histopathology workflows with generative AI-based virtually multiplexed tumour profiling","volume":"6","author":"Pati","year":"2024","journal-title":"Nat. Mach. Intell."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/bs.acr.2024.05.006","article-title":"Advances in Cancer Research, Chapter Ten\u2014Advancements in computer vision and pathology: Unraveling the potential of artificial intelligence for precision diagnosis and beyond","volume":"161","author":"Chang","year":"2024","journal-title":"Adv. Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"217555","DOI":"10.1016\/j.canlet.2025.217555","article-title":"Artificial intelligence in gastrointestinal cancer research: Image learning advances and applications","volume":"614","author":"Zhou","year":"2025","journal-title":"Cancer Lett."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Liatsou, E., Driva, T.S., Vergadis, C., Sakellariou, S., Lykoudis, P., Apostolou, K.G., Tsapralis, D., and Schizas, D. (2025). Current Role of Artificial Intelligence in the Management of Gastric Cancer. Biomedicines, 13.","DOI":"10.3390\/biomedicines13122939"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"111428","DOI":"10.3748\/wjg.v32.i1.111428","article-title":"Artificial intelligence and machine learning-driven advancements in gastrointestinal cancer: Paving the way for precision medicine","volume":"32","author":"Suri","year":"2026","journal-title":"World J. Gastroenterol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"169","DOI":"10.6004\/jnccn.2025.0022","article-title":"Gastric Cancer, Version 2.2025","volume":"23","author":"Ajani","year":"2025","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Health Commission of The People\u2019s Republic of China (2022). National guidelines for diagnosis and treatment of gastric cancer 2022 in China (English version). Chin. J. Cancer Res., 34, 207\u2013237.","DOI":"10.21147\/j.issn.1000-9604.2022.03.04"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1039\/D2AN00063F","article-title":"Nanozyme enhanced magnetic immunoassay for dual-mode detection of gastrin-17","volume":"147","author":"Zheng","year":"2022","journal-title":"Analyst"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.1002\/cam4.4832","article-title":"Simple IHC reveals complex MMR alternations than PCR assays: Validation by LCM and next-generation sequencing","volume":"11","author":"Amemiya","year":"2022","journal-title":"Cancer Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"39","DOI":"10.11604\/pamj.2024.48.39.38445","article-title":"To study the utility of HER2 and Ki-67 as immunohistochemical prognostic markers in comparison to histopathological parameters and tumour, node and metastasis staging in colorectal carcinoma","volume":"48","author":"Naseri","year":"2024","journal-title":"Pan. Afr. Med. J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s43141-023-00539-0","article-title":"Early diagnostic and prognostic biomarkers for gastric cancer: Systems-level molecular basis of subsequent alterations in gastric mucosa from chronic atrophic gastritis to gastric cancer","volume":"21","author":"Selvan","year":"2023","journal-title":"J. Genet. Eng. Biotechnol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41698-025-01224-w","article-title":"Mucin phenotype-based deep learning framework for intestinal metaplasia-carcinogenesis progression prediction","volume":"10","author":"Wu","year":"2026","journal-title":"npj Precis. Onc."},{"key":"ref_57","unstructured":"Wild, C.P., Weiderpass, E., and Stewart, B.W. (2026, February 25). Stomach cancer: Still one of the main cancer types worldwide, World Cancer Report, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK606497\/."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Weiqing, L., and Tai, Z. (2025). Precancerous pathways to gastric cancer: A review of experimental animal models recapitulating the correa cascade. Front. Cell Dev. Biol., 13.","DOI":"10.3389\/fcell.2025.1620756"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1097\/CM9.0000000000003903","article-title":"Helicobacter pylori infection status and evolution of gastric cancer","volume":"138","author":"Zhang","year":"2025","journal-title":"Chin. Med. J."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Liliac, I.M., Ungureanu, B.S., Margaritescu, C., Sacerdotianu, V.M., Saftoiu, A., Mogoanta, L., Moraru, E., and Pirici, D. (2022). E-Cadherin Modulation and Inter-Cellular Trafficking in Tubular Gastric Adenocarcinoma: A High-Resolution Microscopy Pilot Study. Biomedicines, 10.","DOI":"10.3390\/biomedicines10020349"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Stojanovic, B., Jovanovic, I., Dimitrijevic Stojanovic, M., Milosevic, B., Spasic, M., Stojanovic, B.S., Jakovljevic, S., Zornic, N., Jovanovic, D., and Nesic, J. (2025). Galectins as Master Regulators of Gastric Cancer Progression. Cells, 14.","DOI":"10.3390\/cells14141090"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"16","DOI":"10.5230\/jgc.2026.26.e12","article-title":"Evolving Molecular Subtypes of Gastric Cancer: From Past Classifications to Present Consensus and Future Directions for Precision Therapy","volume":"26","author":"Lee","year":"2026","journal-title":"J. Gastric Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"150990","DOI":"10.1016\/j.semdp.2026.150990","article-title":"Molecular Advances in Gastrointestinal Pathology","volume":"43","author":"Das","year":"2026","journal-title":"Semin. Diagn. Pathol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"102737","DOI":"10.1016\/j.ctrv.2024.102737","article-title":"The tumor immune composition of mismatch repair deficient and Epstein-Barr virus-positive gastric cancer: A systematic review","volume":"127","author":"Bos","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1038\/s41591-025-03793-6","article-title":"Global lifetime estimates of expected and preventable gastric cancers across 185 countries","volume":"31","author":"Park","year":"2025","journal-title":"Nat. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"295","DOI":"10.26502\/jcsct.5079252","article-title":"How the Fight against Stomach Cancer can be won","volume":"8","author":"Sebesta","year":"2024","journal-title":"J. Cancer Sci. Clin. Ther."},{"key":"ref_67","unstructured":"Ashman, J.B., Hallemeier, C.L., Beamer, S.E., and Tepper, J.E. (2026). 56\u2014Esophagus-Gastric Cancer. Gunderson & Tepper\u2019s Clinical Radiation Oncology, Elsevier. [6th ed.]. Available online: https:\/\/www.sciencedirect.com\/science\/chapter\/edited-volume\/abs\/pii\/B9780443114762000568."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Oh, S.E., Park, S., Ahn, S., An, J.Y., Lee, J.H., Sohn, T.S., Bae, J.M., and Choi, M.-G. (2023). Prognostic Significance of Esophagogastric Junction Invasion in Patients with Adenocarcinoma of the Cardia or Subcardia. Cancers, 15.","DOI":"10.3390\/cancers15061656"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1097\/CM9.0000000000003259","article-title":"Emerging trends in early-onset gastric cancer","volume":"137","author":"Wang","year":"2024","journal-title":"Chin. Med. J."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Heidary, M., Akrami, S., Madanipour, T., Shakib, N.H., Ari, M.M., Bei, M., Khoshnood, S., Ghanavati, R., and Bazdar, M. (2025). Effect of Helicobacter pylori\u2013induced gastric cancer on gastrointestinal microbiota: A narrative review. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1495596"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jss.2024.01.043","article-title":"Immune Landscape of Epstein-Barr Virus Associated Gastric Cancer: Analysis from a Western Academic Institution","volume":"296","author":"Yee","year":"2024","journal-title":"J. Surg. Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41572-023-00431-8","article-title":"Helicobacter pylori infection","volume":"9","author":"Malfertheiner","year":"2023","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ctrv.2018.03.006","article-title":"Outlooks on Epstein-Barr virus associated gastric cancer","volume":"66","author":"Naseem","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.gastrohep.2015.11.009","article-title":"Hereditary gastric and pancreatic cancer predisposition syndromes","volume":"39","author":"Leoz","year":"2016","journal-title":"Gastroenterol. Hepatol. Engl. Ed."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"99","DOI":"10.5230\/jgc.2024.24.e10","article-title":"Risk Factors of Gastric Cancer and Lifestyle Modification for Prevention","volume":"24","author":"Ko","year":"2024","journal-title":"J. Gastric Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"100273","DOI":"10.1016\/j.jtauto.2025.100273","article-title":"Monitoring the follow-up of autoimmune chronic atrophic gastritis using parietal cell antibodies and markers of gastric function","volume":"10","author":"Panozzo","year":"2025","journal-title":"J. Transl. Autoimmun."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Castellana, C., Eusebi, L.H., Dajti, E., Iascone, V., Vestito, A., Fusaroli, P., Fuccio, L., D\u2019Errico, A., and Zagari, R.M. (2024). Autoimmune Atrophic Gastritis: A Clinical Review. Cancers, 16.","DOI":"10.3390\/cancers16071310"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Martins, B.C., Moura, R.N., Kum, A.S.T., Matsubayashi, C.O., Marques, S.B., and Vaz Safatle-Ribeiro, A. (2023). Endoscopic Imaging for the Diagnosis of Neoplastic and Pre-Neoplastic Conditions of the Stomach. Cancers, 15.","DOI":"10.3390\/cancers15092445"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"308","DOI":"10.30574\/gscbps.2025.33.3.0517","article-title":"Tissue Biomarker in Colorectal Carcinoma","volume":"33","author":"Pradnyani","year":"2025","journal-title":"GSC Biol. Pharm. Sci."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ebiom.2018.01.001","article-title":"SATB2 is a Promising Biomarker for Identifying a Colorectal Origin for Liver Metastatic Adenocarcinomas","volume":"28","author":"Zhang","year":"2018","journal-title":"eBioMedicine"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Murphy, B., Dowling, G., O\u2019Toole, G., and Molloy, A. (2026). Metastatic gastrointestinal adenocarcinoma masquerading as a primary malignant bone tumour in the humerus: A case report and review of the literature. J. Orthop. Rep., 100832.","DOI":"10.1016\/j.jorep.2025.100832"},{"key":"ref_82","first-page":"103184","article-title":"CK7-negative and CK20-Positive intestinal- type gastric adenocarcinoma metastasis to the bladder: A case report of an unprecedented phenotype","volume":"63","year":"2025","journal-title":"Urol. Case Rep."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"47","DOI":"10.59324\/ejmhr.2025.3(6).08","article-title":"Immunohistochemical Expression of CDx2, CK20, Ck7 in Carcinoma of Ampulla of Vater: Clinicopathological Study","volume":"3","author":"Dhannoon","year":"2025","journal-title":"Eur. J. Med. Health Res."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Carbone, A., Alibrahim, M.N., and Gloghini, A. (2025). What Is Still Unclear or Unresolved in Classic Hodgkin Lymphoma Pathobiology, Diagnosis, and Treatment. Hemato, 6.","DOI":"10.3390\/hemato6030020"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Parente, P., Zanelli, M., Sanguedolce, F., Mastracci, L., and Graziano, P. (2020). Hodgkin Reed\u2013Sternberg-Like Cells in Non-Hodgkin Lymphoma. Diagnostics, 10.","DOI":"10.3390\/diagnostics10121019"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"144","DOI":"10.21037\/jgo.2018.08.20","article-title":"Gastrointestinal stromal tumors: A comprehensive review","volume":"10","author":"Parab","year":"2019","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"goaf068","DOI":"10.1093\/gastro\/goaf068","article-title":"An update on gastrointestinal stromal tumors (GISTs) with a focus on extragastrointestinal stromal tumors (EGISTs)","volume":"13","author":"Usama","year":"2025","journal-title":"Gastroenterol. Rep."},{"key":"ref_88","first-page":"e67493","article-title":"Various Markers of Neuroendocrine Tumor: A Narrative Review","volume":"16","author":"Mukherjee","year":"2024","journal-title":"Cureus"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00428-025-04311-2","article-title":"Novel concepts of cell-of origin in neuroendocrine neoplasms","volume":"448","author":"Marinoni","year":"2026","journal-title":"Virchows Arch."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s12022-021-09676-z","article-title":"Challenges in High-grade Neuroendocrine Neoplasms and Mixed Neuroendocrine\/Non-neuroendocrine Neoplasms","volume":"32","year":"2021","journal-title":"Endocr. Pathol."},{"key":"ref_91","first-page":"212","article-title":"Advances and challenges in gastric cancer testing: The role of biomarkers","volume":"22","author":"Sun","year":"2025","journal-title":"Cancer. Biol. Med."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Yao, J., Sun, Q., Wu, H., Zhao, X., Yang, P., Wang, X., Wang, X., Gu, M., Li, J., and Zheng, Y. (2025). Decoding the molecular landscape: HER2 and PD-L1 in advanced gastric cancer. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1567308"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Chen, S., Ding, P., Guo, H., Meng, L., Zhao, Q., and Li, C. (2024). Applications of artificial intelligence in digital pathology for gastric cancer. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1437252"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Kalyuzhny, A.E. (2023). Recent Advances in Chromogens for Immunohistochemistry. Signal Transduction Immunohistochemistry, Humana. Methods in Molecular Biology.","DOI":"10.1007\/978-1-0716-2811-9"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jphotochem.2011.03.008","article-title":"Elementary processes in the eosin-sensitized photooxidation of 3,3\u2032-diaminobenzidine for correlative fluorescence and electron microscopy","volume":"220","author":"Natera","year":"2011","journal-title":"J. Photochem. Photobiol. A-Chem."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"pdb.prot099713","DOI":"10.1101\/pdb.prot099713","article-title":"Detecting Horseradish Peroxidase-Labeled Cells","volume":"2019","author":"Rodig","year":"2019","journal-title":"Cold Spring Harb. Protoc."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/s41598-018-19745-9","article-title":"3,3\u2032-Diaminobenzidine staining interferes with PCR-based DNA analysis","volume":"8","author":"Laurence","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Salvatori, S., Marafini, I., Laudisi, F., Monteleone, G., and Stolfi, C. (2023). Helicobacter pylori and Gastric Cancer: Pathogenetic Mechanisms. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032895"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.3748\/wjg.v23.i20.3721","article-title":"Clinical significance of expression of proliferating cell nuclear antigen and E-cadherin in gastric carcinoma","volume":"23","author":"Hu","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Ionescu, C., Oprea, B., Ciobanu, G., Georgescu, M., Bica, R., Mateescu, G.-O., Huseynova, F., and Veronique Barragan-Montero, V. (2022). The Angiogenic Balance and Its Implications in Cancer and Cardiovascular Diseases: An Overview. Medicina, 58.","DOI":"10.3390\/medicina58070903"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"175586","DOI":"10.1016\/j.ejphar.2023.175586","article-title":"The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF","volume":"949","author":"Ghalehbandi","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.4103\/0366-6999.187842","article-title":"Vascular Endothelial Growth Factor and Cluster of Differentiation 34 for Assessment of Perioperative Bleeding Risk in Gastric Cancer Patients","volume":"129","author":"He","year":"2016","journal-title":"Chin. Med. J."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"637308","DOI":"10.1155\/2014\/637308","article-title":"E-cadherin and gastric cancer: Cause, consequence, and applications","volume":"2014","author":"Liu","year":"2014","journal-title":"BioMed. Res. Int."},{"key":"ref_104","unstructured":"(2026, February 20). Betazoid DAB Chromogen Kit\u2014Biocare Medical. Available online: https:\/\/biocare.net\/product\/betazoid-dab-chromogen-kit\/#:~:text=$195.00%20%E2%80%93%20$3%2C416.00,manually%20or%20on%20automated%20stainers."},{"key":"ref_105","unstructured":"(2026, February 20). Detection and Amplification Systems. Available online: https:\/\/www.abcam.com\/en-us\/technical-resources\/guides\/ihc-guide\/detection-and-amplification-systems?hl=en-US."},{"key":"ref_106","unstructured":"(2026, February 20). Ultrasensitive IHC Detection with HRP-Polymer Conjugates. Available online: https:\/\/www.novusbio.com\/antibody-news\/antibodies\/ultrasensitive-ihc-detection-with-hrp-polymer-conjugates?hl=en-US."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"96","DOI":"10.4161\/19420862.2014.985522","article-title":"High contrast tumor imaging with radio-labeled antibody Fab fragments tailored for optimized pharmacokinetics via PASylation","volume":"7","author":"Mendler","year":"2015","journal-title":"MAbs"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"108022","DOI":"10.1016\/j.pharmthera.2021.108022","article-title":"Therapeutic antibodies\u2014Natural and pathological barriers and strategies to overcome them","volume":"233","author":"Blin","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Choi, S., Park, S., Kim, H., Kang, S.Y., Ahn, S., and Kim, K.M. (2022). Gastric Cancer: Mechanisms, Biomarkers, and Therapeutic Approaches. Biomedicines, 10.","DOI":"10.3390\/biomedicines10030543"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Sato, Y., Okamoto, K., Kawano, Y., Kasai, A., Kawaguchi, T., Sagawa, T., Sogabe, M., Miyamoto, H., and Takayama, T. (2023). Novel Biomarkers of Gastric Cancer: Current Research and Future Perspectives. J. Clin. Med., 12.","DOI":"10.3390\/jcm12144646"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/jcp-2023-208767","article-title":"HER2-low in gastro-oesophageal adenocarcinoma: A real-world pathological perspective","volume":"76","author":"Angerilli","year":"2023","journal-title":"J. Clin. Pathol."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Ricci, A.D., Rizzo, A., Rojas Llimpe, F.L., Di Fabio, F., De Biase, D., and Rihawi, K. (2021). Novel HER2-Directed Treatments in Advanced Gastric Carcinoma: AnotHER Paradigm Shift?. Cancers, 13.","DOI":"10.3390\/cancers13071664"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Bonomi, M., Spada, D., Baiocchi, G.L., Celotti, A., Brighenti, M., and Grizzi, G. (2024). Targeting HER2 in Gastroesophageal Adenocarcinoma: Molecular Features and Updates in Clinical Practice. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25073876"},{"key":"ref_114","first-page":"852748","article-title":"Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications","volume":"2014","author":"Nida","year":"2014","journal-title":"Mol. Biol. Int."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"55","DOI":"10.21037\/tgh.2020.01.08","article-title":"Gastrointestinal cancers: Current biomarkers in esophageal and gastric adenocarcinoma","volume":"5","author":"Dhakras","year":"2020","journal-title":"Transl. Gastroenterol. Hepatol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"103679","DOI":"10.1016\/j.esmoop.2024.103679","article-title":"HER2-low gastric cancer: Is the subgroup targetable?","volume":"9","author":"Shimozaki","year":"2024","journal-title":"ESMO Open"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Ma, C., Wang, X., Guo, J., Yang, B., and Li, Y. (2023). Challenges and future of HER2-positive gastric cancer therapy. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1080990"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.3748\/wjg.v22.i19.4619","article-title":"HER2 testing in gastric cancer: An update","volume":"22","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.flm.2018.11.002","article-title":"Using digital PCR to detect HER2 amplification in breast and gastric cancer patients","volume":"2","author":"Zhou","year":"2018","journal-title":"Front. Lab. Med."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Symeonidis, D., and Tepetes, K. (2019). Techniques and Current Role of Sentinel Lymph Node (SLN) Concept in Gastric Cancer Surgery. Front. Surg., 5.","DOI":"10.3389\/fsurg.2018.00077"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"38372","DOI":"10.18632\/oncotarget.5368","article-title":"Ideal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens","volume":"6","author":"Ahn","year":"2015","journal-title":"Oncotarget"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s10120-014-0453-0","article-title":"HER2 testing in paired biopsy and excision specimens of gastric cancer: The reliability of the scoring system and the clinicopathological factors relevant to discordance","volume":"19","author":"Huang","year":"2016","journal-title":"Gastric Cancer"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/PAT.0b013e3283513e8b","article-title":"Comparison of four immunohistochemical tests and FISH for measuring HER2 expression in gastric carcinomas","volume":"44","author":"Cho","year":"2012","journal-title":"Pathology"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"661","DOI":"10.4143\/crt.2019.718","article-title":"PD-L1 Testing in Gastric Cancer by the Combined Positive Score of the 22C3 PharmDx and SP263 Assay with Clinically Relevant Cut-offs","volume":"52","author":"Park","year":"2020","journal-title":"Cancer Res. Treat."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.pathol.2016.09.064","article-title":"A potential pitfall in evaluating HER2 immunohistochemistry for gastric signet ring cell carcinomas","volume":"49","author":"Woo","year":"2017","journal-title":"Pathology"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.prp.2016.02.007","article-title":"The relation between percentage of immunostained cells and amplification status in breast cancers with equivocal result for Her2 immunohistochemistry","volume":"212","author":"Onguru","year":"2016","journal-title":"Pathol. Res. Pract."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"101624","DOI":"10.1016\/j.tranon.2023.101624","article-title":"Research progress of antibody-drug conjugates therapy for HER2-low expressing gastric cancer","volume":"29","author":"Yu","year":"2023","journal-title":"Transl. Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"102646","DOI":"10.1016\/j.clinre.2025.102646","article-title":"The impact of low HER2 expression on clinicopathological features and clinical outcomes in patients with metastatic gastric cancer","volume":"49","author":"Guliyev","year":"2025","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Huang, D., Sun, F., Li, S., and Ke, L. (2025). Efficacy and safety of antibody-drug conjugates for HER2-expressing advanced gastric and gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1668511"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"6438","DOI":"10.3748\/wjg.v19.i38.6438","article-title":"HER2 in gastric cancer: Comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays","volume":"19","author":"Wohnrath","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/1479-5876-12-160","article-title":"The validation of a novel method combining both HER2 immunohistochemistry and HER2 dual-colour silver in situ hybridization on one slide for gastric carcinoma testing","volume":"12","author":"Werner","year":"2014","journal-title":"J. Transl. Med."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.3892\/ol.2020.11731","article-title":"Comparing human epidermal growth factor receptor 2 amplification and expression using immunohistochemistry and silver in situ hybridisation in gastric carcinoma and lymph node metastasis","volume":"20","author":"Yilmaz","year":"2020","journal-title":"Oncol. Lett."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"7235","DOI":"10.2147\/OTT.S100643","article-title":"Trastuzumab in the management of gastroesophageal cancer: Patient selection and perspectives","volume":"9","author":"Davidson","year":"2016","journal-title":"Onco. Targets Ther."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1016\/j.ajpath.2025.08.014","article-title":"Cross-Modality Learning for Predicting Immunohistochemistry Biomarkers from Hematoxylin and Eosin-Stained Whole Slide Images","volume":"195","author":"Das","year":"2025","journal-title":"Am. J. Pathol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/s41379-020-0644-7","article-title":"Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC)","volume":"34","author":"Mulder","year":"2021","journal-title":"Mod. Pathol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s12935-020-01273-0","article-title":"Heterogeneous programmed death-ligand 1 expression in gastric cancer: Comparison of tissue microarrays and whole sections","volume":"20","author":"Ye","year":"2020","journal-title":"Cancer Cell Int."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"100793","DOI":"10.1016\/j.modpat.2025.100793","article-title":"Concordance Between the PD-L1 Tumor Area Positivity Score and Combined Positive Score for Gastric or Esophageal Cancers Treated with Tislelizumab","volume":"38","author":"Moehler","year":"2025","journal-title":"Mod. Pathol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1038\/s41598-021-81667-w","article-title":"PD-L1 overexpression in EBV-positive gastric cancer is caused by unique genomic or epigenomic mechanisms","volume":"11","author":"Nakano","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s12672-022-00479-0","article-title":"PD-L1 expression in EBV associated gastric cancer: A systematic review and meta-analysis","volume":"13","author":"Lima","year":"2022","journal-title":"Discov. Oncol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1200\/JCO.2018.36.4_suppl.9","article-title":"Associations of PD-1 and PD-L1 expression with mismatch repair status and prognosis in chemoradiotherapy-na\u00efve esophageal and gastric adenocarcinoma","volume":"36","author":"Svensson","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"109317","DOI":"10.1016\/j.intimp.2022.109317","article-title":"Immune checkpoint inhibitors plus chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric and esophageal cancers: A systematic review and meta-analysis","volume":"113","author":"Noori","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"100154","DOI":"10.1016\/j.modpat.2023.100154","article-title":"High Interobserver Variability Among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma","volume":"36","author":"Wang","year":"2023","journal-title":"Mod. Pathol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/s41379-021-00823-9","article-title":"PD-L1 expression in gastric cancer: Interchangeability of 22C3 and 28-8 pharmDx assays for responses to immunotherapy","volume":"34","author":"Ahn","year":"2021","journal-title":"Mod. Pathol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1111\/1759-7714.15319","article-title":"Comparison of SP263 and 22C3 pharmDx assays to test programmed death ligand-1 (PD-L1) expression in surgically resected non-small cell lung cancer","volume":"15","author":"Shigeta","year":"2024","journal-title":"Thorac. Cancer"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"pkaa054","DOI":"10.1093\/jncics\/pkaa054","article-title":"Universal Screening of Gastrointestinal Malignancies for Mismatch Repair Deficiency at Stanford","volume":"4","author":"Abrha","year":"2020","journal-title":"JNCI Cancer Spectr."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ejso.2019.08.025","article-title":"Prognostic value of mismatch repair deficiency in patients with advanced gastric cancer, treated by surgery and adjuvant 5-fluorouracil and leucovorin chemoradiotherapy","volume":"46","author":"Kim","year":"2020","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1611719","DOI":"10.3389\/pore.2024.1611719","article-title":"Microsatellite instability and mismatch repair protein deficiency: Equal predictive markers","volume":"30","author":"Maja","year":"2024","journal-title":"Pathol. Oncol. Res."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1038\/s41379-022-01109-4","article-title":"Detecting mismatch repair deficiency in solid neoplasms: Immunohistochemistry, microsatellite instability, or both?","volume":"35","author":"Wang","year":"2022","journal-title":"Mod. Pathol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.bulcan.2018.12.008","article-title":"MSI\/MMR-deficient tumor diagnosis: Which standard for screening and for diagnosis? Diagnostic modalities for the colon and other sites: Differences between tumors","volume":"106","author":"Svrcek","year":"2019","journal-title":"Bull. Cancer"},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Reitsam, N.G., M\u00e4rkl, B., Dintner, S., Waidhauser, J., Vlasenko, D., and Grosser, B. (2022). Concurrent loss of MLH1, PMS2 and MSH6 immunoexpression in digestive system cancers indicating a widespread dysregulation in DNA repair processes. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1019798"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s12029-023-01003-5","article-title":"Management of Microsatellite Instability High (MSI-H) Gastroesophageal Adenocarcinoma","volume":"55","author":"Zhou","year":"2024","journal-title":"J. Gastrointest. Cancer"},{"key":"ref_152","first-page":"1183","article-title":"Microsatellite Instability (MSI) and Mismatch Repair (MMR) Protein in Gastric Cancer Patients: Clinical Significance","volume":"5","author":"Wang","year":"2025","journal-title":"J. Oncol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s44272-024-00017-9","article-title":"Microsatellite instability in gastric cancer: Molecular features and clinical implications","volume":"3","author":"Zhang","year":"2024","journal-title":"Clin. Cancer Bull."},{"key":"ref_154","first-page":"4269781","article-title":"The Clinicopathological Characteristics and Prognoses of dMMR Gastric Adenocarcinoma Patients","volume":"9","author":"Wang","year":"2021","journal-title":"Gastroenterol. Res. Pract."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.1016\/j.ejso.2022.11.491","article-title":"Presentation of 4 cases of Lymphoepithelioma-like gastric carcinoma","volume":"49","author":"Orcajo","year":"2023","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/1878-0261.70178","article-title":"A subset of MMR-proficient colon cancers responds to neoadjuvant immunotherapy","volume":"20","author":"Piumatti","year":"2026","journal-title":"Mol. Oncol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"e6994","DOI":"10.1002\/cam4.6994","article-title":"Mismatch repair protein deficiency and its implications on distant metastasis in colorectal cancer: A comprehensive analysis","volume":"13","author":"Fan","year":"2024","journal-title":"Cancer Med."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"5722","DOI":"10.1097\/JS9.0000000000001680","article-title":"Clinical status and future prospects of neoadjuvant immunotherapy for localized mismatch repair-deficient cancers: A review","volume":"110","author":"Li","year":"2024","journal-title":"Int. J. Surg."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.5858\/arpa.2018-0201-OA","article-title":"Screening for Lynch Syndrome by Immunohistochemistry of Mismatch Repair Proteins: Significance of Indeterminate Result and Correlation with Mutational Studies","volume":"143","author":"Sarode","year":"2019","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/s41379-019-0414-6","article-title":"Retained mismatch repair protein expression occurs in approximately 6% of microsatellite instability-high cancers and is associated with missense mutations in mismatch repair genes","volume":"33","author":"Hechtman","year":"2020","journal-title":"Mod. Pathol."},{"key":"ref_161","first-page":"e2300648","article-title":"Analysis of Concordance Between Next-Generation Sequencing Assessment of Microsatellite Instability and Immunohistochemistry-Mismatch Repair from Solid Tumors","volume":"8","author":"Krause","year":"2024","journal-title":"JCO Precis. Oncol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"17588359231217967","DOI":"10.1177\/17588359231217967","article-title":"Zolbetuximab for Claudin18.2-positive gastric or gastroesophageal junction cancer","volume":"16","author":"Kubota","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1159\/000545769","article-title":"Computer-Aided Diagnostics Helps Accurately Determine Different Expression Levels of Claudin-18.2 in Gastric Cancer","volume":"92","author":"Girkinger","year":"2025","journal-title":"Pathobiology"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"100844","DOI":"10.1016\/j.modpat.2025.100844","article-title":"Analytical and Clinical Performance of the VENTANA CLDN18 (43-14A) RxDx Assay in Gastric and Gastroesophageal Junction Adenocarcinoma Tissue Samples in SPOTLIGHT and GLOW","volume":"38","author":"Stratton","year":"2025","journal-title":"Mod. Pathol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1200\/JCO.2023.41.16_suppl.4035","article-title":"Global prevalence of CLDN18.2 in patients with locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG\/GEJ) adenocarcinoma: Biomarker analysis of two zolbetuximab phase 3 studies (SPOTLIGHT and GLOW)","volume":"41","author":"Shitara","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"oyaf185","DOI":"10.1093\/oncolo\/oyaf185","article-title":"New tool in the toolbox: Patient selection for zolbetuximab in advanced treatment-na\u00efve gastric\/gastroesophageal junction adenocarcinoma","volume":"30","author":"Grewal","year":"2025","journal-title":"Oncologist"},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Dominguez Wiscovitch, A., Sanchez Mendez, R.J., and Chuy, J. (2025). CLDN18.2-Targeted Therapy in Gastrointestinal Cancers. Cancers, 17.","DOI":"10.3390\/cancers17233764"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.21037\/jgo-2025-637","article-title":"Claudin 18.2 in gastroesophageal adenocarcinoma: Prevalence, biomarker associations, and implications for equity","volume":"16","author":"Zatsepina","year":"2025","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.21873\/invivo.13954","article-title":"Claudin 18.2 Expression in Gastric Tumors and Other Tumor Types with Gastric Epithelium-like Differentiation","volume":"39","author":"Kim","year":"2025","journal-title":"In Vivo"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"100589","DOI":"10.1016\/j.modpat.2024.100589","article-title":"Claudin-18.2 Immunohistochemical Evaluation in Gastric and Gastroesophageal Junction Adenocarcinomas to Direct Targeted Therapy: A Practical Approach","volume":"37","author":"Fassana","year":"2024","journal-title":"Mod. Pathol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"17648","DOI":"10.1038\/s41598-024-68411-w","article-title":"Heterogeneity of claudin 18.2 expression in metastatic gastric cancer","volume":"14","author":"Choi","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"303","DOI":"10.5230\/jgc.2025.25.e2","article-title":"Discordance in Claudin 18.2 Expression Between Primary and Metastatic Lesions in Patients with Gastric Cancer","volume":"25","author":"Son","year":"2025","journal-title":"J. Gastric Cancer"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"104000","DOI":"10.1016\/j.esmoop.2024.104000","article-title":"Clinicopathological analysis of claudin 18.2 focusing on intratumoral heterogeneity and survival in patients with metastatic or unresectable gastric cancer","volume":"9","author":"Kim","year":"2024","journal-title":"ESMO Open"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s10120-025-01609-7","article-title":"Heterogeneity of predictive biomarker expression in gastric and esophago-gastric junction carcinoma with peritoneal dissemination","volume":"28","author":"Angerilli","year":"2025","journal-title":"Gastric Cancer"},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Mathias-Machado, M.C., de Jesus, V.H.F., J\u00e1come, A., Donadio, M.D., Aruquipa, M.P.S., Fogacci, J., Cunha, R.G., da Silva, L.M., and Peixoto, R.D. (2024). Claudin 18.2 as a New Biomarker in Gastric Cancer-What Should We Know?. Cancers, 16.","DOI":"10.3390\/cancers16030679"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"e2400710","DOI":"10.1200\/PO-24-00710","article-title":"Prevalence of FGFR2b Protein Overexpression in Advanced Gastric Cancers During Prescreening for the Phase III FORTITUDE-101 Trial","volume":"9","author":"Rha","year":"2025","journal-title":"JCO Precis. Oncol."},{"key":"ref_177","doi-asserted-by":"crossref","unstructured":"Lages Dos Santos, J., Caetano Oliveira, R., and Gama, J.M. (2025). The Role of FGFR2 as a Novel Biomarker for Treatment of Gastric Cancer-A Literature Review. Medicina, 61.","DOI":"10.3390\/medicina61111890"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"102971","DOI":"10.1016\/j.ctrv.2025.102971","article-title":"FGFR2b protein overexpression: An emerging biomarker in gastric and gastroesophageal junction adenocarcinoma","volume":"139","author":"Smyth","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.1038\/s41598-021-84107-x","article-title":"Clinical difference between fibroblast growth factor receptor 2 subclass, type IIIb and type IIIc, in gastric cancer","volume":"11","author":"Yashiro","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"100867","DOI":"10.1016\/j.modpat.2025.100867","article-title":"A Global Ring Study: Concordance Between Ventana PATHWAY Anti-HER2\/neu (4B5) Companion Diagnostic Assay and Comparators in Detecting HER2-Low Breast Cancer","volume":"38","author":"Schildhaus","year":"2025","journal-title":"Mod. Pathol."},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Koh, J., Nam, S.K., Lee, Y.W., Kim, J.W., Lee, K.-W., Ock, C.-Y., Oh, D.-Y., Ahn, S.-H., Kim, H.-H., and Kang, K.-W. (2019). Trastuzumab Specific Epitope Evaluation as a Predictive and Prognostic Biomarker in Gastric Cancer Patients. Biomolecules, 9.","DOI":"10.3390\/biom9120782"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.21037\/jgo-21-505","article-title":"PD-L1 immunohistochemistry comparison of 22C3 and 28-8 assays for gastric cancer","volume":"12","author":"Narita","year":"2021","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"Ahn, S., Hwang, I., Kim, Y., Lee, S., Cho, Y., Kang, S.Y., Kim, D.G., Lee, J., and Kim, K.-M. (2025). Best Practice PD-L1 Staining and Interpretation in Gastric Cancer Using PD-L1 IHC PharmDx 22C3 and PD-L1 IHC PharmDx 28-8 Assays, with Reference to Common Issues and Solutions. Biomedicines, 13.","DOI":"10.3390\/biomedicines13112824"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s10120-024-01500-x","article-title":"Discordant PD-L1 results between 28-8 and 22C3 assays are associated with outcomes of gastric cancer patients treated with nivolumab plus chemotherapy","volume":"27","author":"Kim","year":"2024","journal-title":"Gastric Cancer"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"177","DOI":"10.5230\/jgc.2025.25.e4","article-title":"PD-L1 as a Biomarker in Gastric Cancer Immunotherapy","volume":"25","author":"Cho","year":"2025","journal-title":"J. Gastric Cancer"},{"key":"ref_186","first-page":"e75206","article-title":"Zolbetuximab for Unresectable and Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma: A Review of Literature","volume":"16","author":"Samanta","year":"2024","journal-title":"Cureus"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"100206","DOI":"10.1016\/j.esmogo.2025.100206","article-title":"Temporal dynamics of CLDN18.2 expression following zolbetuximab treatment in advanced gastric cancer","volume":"9","author":"Yamamoto","year":"2025","journal-title":"ESMO Gastrointest. Oncol."},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"Easaw, J.C., Lim, H.J., Karachiwala, H., Gill, S., Zhu, X., and Bateman, J. (2025). Zolbetuximab or Immunotherapy as the Initial Targeted Therapy in CLDN18.2-Positive, HER2-Negative Advanced Gastric Cancer: Weighing the Options. Curr. Oncol., 32.","DOI":"10.3390\/curroncol32110648"},{"key":"ref_189","unstructured":"Serani, S. (2026, February 25). Zolbetuximab Scores FDA Approval in CLDN 18.2+ Gastric\/GEJ Cancer. FDA Briefs. Available online: https:\/\/www.targetedonc.com\/view\/zolbetuximab-scores-fda-approval-in-cldn-18-2-gastric-gej-cancer."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/S1470-2045(22)00603-9","article-title":"Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): A randomised, double-blind, placebo-controlled, phase 2 study","volume":"23","author":"Wainberg","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_191","doi-asserted-by":"crossref","unstructured":"Njoku, V.C.E., Lee, Y., Ramesh, J., Kubatka, P., and B\u00fcsselberg, D. (2025). Precision Antibody Therapy in Gastric and Gastroesophageal Cancer: Targeting FGFR2b, CLDN18.2, and VEGFR2. Cells, 14.","DOI":"10.3390\/cells14211672"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"192","DOI":"10.5230\/jgc.2025.25.e3","article-title":"Spatial and Temporal Tumor Heterogeneity in Gastric Cancer: Discordance of Predictive Biomarkers","volume":"25","author":"Lee","year":"2025","journal-title":"J. Gastric Cancer."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/PGP.0000000000000582","article-title":"CDX2, SATB2, GATA3, TTF1, and PAX8 Immunohistochemistry in Krukenberg Tumors","volume":"39","year":"2020","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"61","DOI":"10.55729\/2000-9666.1548","article-title":"Gastric Adenocarcinoma with Enteroblastic Differentiation Presenting as Lung Nodules: A Diagnostic Dilemma","volume":"15","author":"Evani","year":"2025","journal-title":"J. Community Hosp. Intern. Med. Perspect."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/jgh3.13014","article-title":"Gastric adenocarcinoma of the fundic gland type: A review of the literature","volume":"7","author":"Zhai","year":"2023","journal-title":"JGH Open"},{"key":"ref_196","doi-asserted-by":"crossref","unstructured":"Biskupski, M., Brachet, A., Hunek, G., Karabin, A., Czerski, M., Bojarska, W., Karpi\u0144ski, R., Teresi\u0144ski, G., Forma, A., and Baj, J. (2026). Gastric Cancer Epithelial-Mesenchymal Transition-The Role of Micro-RNA. Cancers, 18.","DOI":"10.3390\/cancers18030462"},{"key":"ref_197","first-page":"6753","article-title":"Predicting lymph node metastasis in gastric adenocarcinoma: Role of tumor budding and immunohistochemical expression of E-cadherin","volume":"11","author":"Nguyen","year":"2024","journal-title":"Biomed. Res. Ther."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"118057","DOI":"10.1016\/j.biopha.2025.118057","article-title":"Role of tumor suppressor genes P53 and PTEN in CD44-mediated gastric adenocarcinoma multidrug resistance","volume":"187","author":"Herraeza","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"ref_199","doi-asserted-by":"crossref","unstructured":"Nemtsova, M.V., Kuznetsova, E.B., and Bure, I.V. (2023). Chromosomal Instability in Gastric Cancer: Role in Tumor Development, Progression, and Therapy. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242316961"},{"key":"ref_200","doi-asserted-by":"crossref","unstructured":"Monge, C., Waldrup, B., Carranza, F.G., and Velazquez-Villarreal, E. (2025). Molecular Alterations in TP53, WNT, PI3K, TGF-Beta, and RTK\/RAS Pathways in Gastric Cancer Among Ethnically Heterogeneous Cohorts. Cancers, 17.","DOI":"10.1101\/2025.02.22.25322719"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"6203","DOI":"10.1038\/s41467-023-41805-6","article-title":"Genomic signatures of past and present chromosomal instability in Barrett\u2019s esophagus and early esophageal adenocarcinoma","volume":"14","author":"Bao","year":"2023","journal-title":"Nat Commun"},{"key":"ref_202","first-page":"9097621","article-title":"Tumor Budding and E-Cadherin Loss as Robust Prognostic Markers in Pancreatic Ductal Adenocarcinoma: A Study in a Turkish Patient Cohort","volume":"14","author":"Pasaoglu","year":"2025","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1369\/0022155421995600","article-title":"Impact of Preanalytical Factors on the Measurement of Tumor Tissue Biomarkers Using Immunohistochemistry","volume":"69","author":"Bagchi","year":"2021","journal-title":"J. Histochem. Cytochem."},{"key":"ref_204","unstructured":"Streckfus, C.F. (2018). Capter 1, Detection Systems in Immunohistochemistry. Immunohistochemistry\u2014The Ageless Biotechnology, Intechopen."},{"key":"ref_205","doi-asserted-by":"crossref","unstructured":"Hnasko, R. (2015). Tyramide Signal Amplification for Immunofluorescent Enhancement. ELISA, Humana. Methods in Molecular Biology.","DOI":"10.1007\/978-1-4939-2742-5"},{"key":"ref_206","doi-asserted-by":"crossref","unstructured":"Yu, X., Huang, C., Song, Y., Zhang, C., You, D., Dong, X., Wu, D., Meeker, A.K., Feng, H., and Wang, Y. (2025). Research progress and perspectives on the application of tyramide signal amplification-based multiplex immunohistochemistry\/immunofluorescence: A bibliometrics analysis. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1473414"},{"key":"ref_207","doi-asserted-by":"crossref","unstructured":"Vancurova, I., and Zhu, Y. (2020). Detection of Cytokine Receptors Using Tyramide Signal Amplification for Immunofluorescence. Immune Mediators in Cancer, Humana. Methods in Molecular Biology.","DOI":"10.1007\/978-1-0716-0247-8"},{"key":"ref_208","doi-asserted-by":"crossref","unstructured":"Ivanovic, T., Bo\u017eic, D., Benzon, B., \u010capkun, V., Vukojevi\u0107, K., and Durdov, M.G. (2023). Histological Type, Cytotoxic T Cells and Macrophages in the Tumor Microenvironment Affect the PD-L1 Status of Gastric Cancer. Biomedicines, 11.","DOI":"10.3390\/biomedicines11030709"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"126898","DOI":"10.1016\/j.saa.2025.126898","article-title":"Tyramide signal amplification-based detection system: A novel approach to improve detection efficiency for circulating tumor cells","volume":"346","author":"Chen","year":"2026","journal-title":"Spectrochim. Acta A Mol. Biomol. Spectrosc."},{"key":"ref_210","doi-asserted-by":"crossref","unstructured":"Singh, C., Bali, N., Coughlin, G.M., Xu, J., Polansky, J.Y., Herget, U., Gilbert, M.S., Cammidge, T., Spigolon, G., and Smirnova, Y. (2025). Next-generation hybridization chain reaction tools with enhanced sensitivities to detect challenging targets. bioRxiv, preprint.","DOI":"10.1101\/2025.09.09.675218"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"dev165753","DOI":"10.1242\/dev.165753","article-title":"Third-generation in situ hybridization chain reaction: Multiplexed, quantitative, sensitive, versatile, robust","volume":"145","author":"Choi","year":"2018","journal-title":"Development"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1021\/acs.analchem.0c03563","article-title":"Ultrasensitive Detection of RNA with Single-Base Resolution by Coupling Electrochemical Sensing Strategy with Chimeric DNA Probe-Aided Ligase Chain Reaction","volume":"93","author":"Zhong","year":"2021","journal-title":"Anal. Chem."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/cyto.a.20970","article-title":"Tyramide signal amplification for analysis of kinase activity by intracellular flow cytometry","volume":"77","author":"Clutter","year":"2010","journal-title":"Cytometry A"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"13363","DOI":"10.1038\/s41598-023-39687-1","article-title":"Inactivation kinetics of horseradish peroxidase (HRP) by hydrogen peroxide","volume":"13","author":"Contreras","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"605","DOI":"10.5230\/jgc.2025.25.e46","article-title":"Distinct Immunosuppressive Tumor Microenvironment in Gastric Cancer with Peritoneal Metastasis","volume":"25","author":"Kim","year":"2025","journal-title":"J. Gastric Cancer"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1158\/2767-9764.CRC-24-0302","article-title":"The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric Cancer","volume":"5","author":"Koganemaru","year":"2025","journal-title":"Cancer Res. Commun."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1158\/2326-6066.CIR-25-0625","article-title":"Distinct Spatially Resolved Tumor Microenvironment Trajectories Define Benefit from Ramucirumab plus Pembrolizumab in Refractory PD-L1+ Gastric Cancer","volume":"14","author":"Lim","year":"2026","journal-title":"Cancer Immunol. Res."},{"key":"ref_218","doi-asserted-by":"crossref","unstructured":"Liu, F., Li, G., Zheng, Y., Liu, Y., and Liu, K. (2025). Multiplex imaging analysis of the tumor immune microenvironment for guiding precision immunotherapy. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1617906"},{"key":"ref_219","doi-asserted-by":"crossref","unstructured":"Sheng, W., Zhang, C., Mohiuddin, T.M., Al-Rawe, M., Zeppernick, F., Falcone, F.H., Meinhold-Heerlein, I., and Hussain, A.F. (2023). Multiplex Immunofluorescence: A Powerful Tool in Cancer Immunotherapy. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24043086"},{"key":"ref_220","doi-asserted-by":"crossref","unstructured":"Cozac-Sz\u0151ke, A.-R., Cozac, D.A., Negovan, A., Tinca, A.C., Vilaia, A., Cocuz, I.-G., Sab\u0103u, A.H., Niculescu, R., Chiorean, D.M., and Tomut, A.N. (2025). Immune Cell Interactions and Immune Checkpoints in the Tumor Microenvironment of Gastric Cancer. Int. J. Mol. Sci., 26.","DOI":"10.20944\/preprints202501.0608.v1"},{"key":"ref_221","doi-asserted-by":"crossref","unstructured":"Gupta, B., Yang, G., and Key, M. (2024). Novel Chromogens for Immunohistochemistry in Spatial Biology. Cells, 13.","DOI":"10.20944\/preprints202404.1670.v1"},{"key":"ref_222","doi-asserted-by":"crossref","unstructured":"Baptista Freitas, M., Gullo, I., Leit\u00e3o, D., \u00c1guas, L., Oliveira, C., Pol\u00f3nia, A., Gomes, J., Carneiro, F., Reis, C.A., and Duarte, H.D. (2024). HER2 and PD-L1 Expression in Gastric and Gastroesophageal Junction Cancer: Insights for Combinatorial Targeting Approaches. Cancers, 16.","DOI":"10.3390\/cancers16061227"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"102308","DOI":"10.1016\/j.jddst.2020.102308","article-title":"Quantum dots: Prospectives, toxicity, advances and applications","volume":"61","author":"Gidwani","year":"2021","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_224","doi-asserted-by":"crossref","unstructured":"Liang, Z., Khawar, M.B., Liang, J., and Sun, H. (2021). Bio-Conjugated Quantum Dots for Cancer Research: Detection and Imaging. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.749970"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"996","DOI":"10.3892\/ol.2012.870","article-title":"In vitro gastric cancer cell imaging using near-infrared quantum dot-conjugated CC49","volume":"4","author":"Zhang","year":"2012","journal-title":"Oncol. Lett."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"94907163","DOI":"10.26599\/NR.2025.94907163","article-title":"Application of quantum dots in cancer diagnosis and treatment: Advances and perspectives","volume":"18","author":"Li","year":"2025","journal-title":"Nano Res."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3892\/ijmm.2025.5617","article-title":"New advances of nanozymes for the diagnosis and treatment of digestive system diseases","volume":"56","author":"Xie","year":"2025","journal-title":"Int. J. Mol. Med."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"4632","DOI":"10.1021\/acsami.5c21149","article-title":"Smart Designer Nanozymes for Precision Cancer Therapy: Recent Advances and Prospects","volume":"18","author":"Khan","year":"2026","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1186\/s12951-024-02848-z","article-title":"Integrated triple signal amplification strategy for ultrasensitive electrochemical detection of gastric cancer-related microRNA utilizing MoS2-based nanozyme, hybridization chain reaction, and horseradish peroxidase","volume":"22","author":"Ma","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/PAI.0000000000000930","article-title":"Quantitative Image Analysis for Tissue Biomarker Use: A White Paper from the Digital Pathology Association","volume":"29","author":"Lara","year":"2021","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1093\/jnen\/nlaf026","article-title":"Digital pathology in tau research: A comparison of QuPath and HALO","volume":"84","author":"Gonzalez","year":"2025","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"104246","DOI":"10.1016\/j.labinv.2025.104246","article-title":"Comparison of QuPath and HALO Platforms for Analysis of the Tumor Microenvironment in Prostate Cancer","volume":"105","author":"Zhang","year":"2025","journal-title":"Lab Investig."},{"key":"ref_233","doi-asserted-by":"crossref","unstructured":"Han, T., Zhuo, M., Song, Z., Chen, P., Chen, S., Zhang, W., Zhou, Y., Li, H., Zhang, D., and Lin, X. (2025). Automated interpretation of PD-L1 CPS based on multi-AI models integration strategy in gastric cancer. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1614099"},{"key":"ref_234","doi-asserted-by":"crossref","unstructured":"Fu, M., Xu, J., Lv, Y., and Jin, B. (2025). Artificial intelligence in advanced gastric cancer: A comprehensive review of applications in precision oncology. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1630628"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"410","DOI":"10.5230\/jgc.2023.23.e25","article-title":"Artificial Intelligence in the Pathology of Gastric Cancer","volume":"23","author":"Choi","year":"2023","journal-title":"J. Gastric Cancer"},{"key":"ref_236","unstructured":"Shafik, W., Dutta, P.K., and Pattanaik, P. (2026). AI-Assisted Histopathological Image Analysis for Automated Gastric Cancer Detection. The Convergence of Federated Learning and Healthcare 5.0 and Beyond: A New Era of Intelligent Health Systems, Springer. Studies in Computational Intelligence."},{"key":"ref_237","doi-asserted-by":"crossref","unstructured":"Xia, S., Xia, Y., Liu, T., Luo, Y., and Pang, P.C. (2025). Application of deep learning models in gastric cancer pathology image analysis: A systematic scoping review. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-14662-3"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"34204","DOI":"10.1038\/s41598-025-15702-5","article-title":"An interpretable hybrid deep learning framework for gastric cancer diagnosis using histopathological imaging","volume":"15","author":"Ren","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_239","doi-asserted-by":"crossref","unstructured":"Ma, J., Yang, F., Yang, R., Li, Y., and Chen, Y. (2025). Interpretable deep learning for gastric cancer detection: A fusion of AI architectures and explainability analysis. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1596085"},{"key":"ref_240","doi-asserted-by":"crossref","unstructured":"Han, Z., Lan, J., Wang, T., Hu, Z., Huang, Y., Deng, Y., Zhang, H., Wang, J., Chen, M., and Jiang, H. (2022). A Deep Learning Quantification Algorithm for HER2 Scoring of Gastric Cancer. Front. Neurosci., 16.","DOI":"10.3389\/fnins.2022.877229"},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"1611964","DOI":"10.3389\/pore.2025.1611964","article-title":"A novel automated IHC staining system for quality control application in ALK immunohistochemistry testing","volume":"31","author":"Hou","year":"2025","journal-title":"Pathol. Oncol. Res."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s44290-025-00232-w","article-title":"Sustainable building practices for modern clinical laboratories","volume":"2","author":"Olaiya","year":"2025","journal-title":"Discov. Civ. Eng."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"110985","DOI":"10.1016\/j.clinbiochem.2025.110985","article-title":"Waste management and environmental health impact: Sustainable laboratory medicine as mitigating response","volume":"139","author":"Nwobi","year":"2025","journal-title":"Clin. Biochem."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"e2404411","DOI":"10.1002\/advs.202404411","article-title":"The Environmental Impact of Medical Imaging Agents and the Roadmap to Sustainable Medical Imaging","volume":"12","author":"Pichler","year":"2025","journal-title":"Adv. Sci."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"116317","DOI":"10.1016\/j.biopha.2024.116317","article-title":"Mapping spatial heterogeneity in gastric cancer microenvironment","volume":"172","author":"Wang","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"343","DOI":"10.4143\/crt.2023.1302","article-title":"Applicability of Spatial Technology in Cancer Research","volume":"56","author":"Ahn","year":"2024","journal-title":"Cancer Res. Treat."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1136\/gutjnl-2024-332901","article-title":"Spatial dissection of tumour microenvironments in gastric cancers reveals the immunosuppressive crosstalk between CCL2+ fibroblasts and STAT3-activated macrophages","volume":"74","author":"Lee","year":"2025","journal-title":"Gut"},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"350\u2212369","DOI":"10.3934\/medsci.2025024","article-title":"Harnessing big data in pathology for precision medicine in gastric cancer: AI-integrated clinical applications","volume":"12","author":"Ma","year":"2025","journal-title":"AIMS Med. Sci."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/4\/683\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T04:55:45Z","timestamp":1775451345000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/4\/683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":248,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["medicina62040683"],"URL":"https:\/\/doi.org\/10.3390\/medicina62040683","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,3]]}}}